Diagnostics Solutions Strategic Priorities

Investing CHF >600m to increase supply chain capacities Driving to unprecedented volume in record time Consumables • 60 new manufacturing lines • 17 locations with 5 new partners 8 new manufacturing lines • 1 new biotech facility Raw materials Reagents • 20 new manufacturing lines • 4 major facility expansions • CHF >600m investment • >1,200 new employees ⚫ 1 new manufacturing space Rx Only cobas SARS-CoV-2 V IVD G Roche Instruments 25

View entire presentation